Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice

Psychiatric Services

Volumn 56, Issue 3, 2005, Pages 283-291

  West, Joyce C ^a   Wilk, Joshua E ^a   Olfson, Mark ^b   Rae, Donald S ^a   Marcus, Steve ^c   Narrow, William E ^a   Pincus, Harold A ^d   Regier, Darrel A ^a  

^a Practice Research Network   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; MESORIDAZINE; NEUROLEPTIC AGENT; STABILIZING AGENT; THIORIDAZINE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE QUALITY; HUMAN; MALE; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL RESEARCH; MENTAL PATIENT; POPULATION RESEARCH; PRACTICE GUIDELINE; PSYCHIATRIC TREATMENT; PSYCHIATRIST; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL CARE; REHABILITATION CENTER; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; CASE MANAGEMENT; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; EMPLOYMENT, SUPPORTED; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PSYCHIATRY; REHABILITATION, VOCATIONAL; SCHIZOPHRENIA; UNITED STATES;

EID: 14744291781     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.56.3.283     Document Type: Article

References (34)

1. Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158:518-526, 2001
2. Practice Guidelines for the Treatment of Patients with Schizophrenia. American Psychiatric Press, Arlington, Va, 2004
3. Siris SG, Bermanzohn PC, Mason SE, et al: Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Archives of General Psychiatry 51:109-115, 1994
4. Wolkowitz OM, Pickar D: Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. American Journal of Psychiatry 148:714-726, 1991
5. Casey DE, Daniel DG, Wassef AA, et al: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182-192, 2003
6. McCue RE, Waheed R, Urcuyo L: Polypharmacy in patients with schizophrenia. Journal of Clinical Psychiatry 64:984-989, 2003
7. Huxley NA, Rendall M, Sederer L: Psychosocial treatments in schizophrenia: a review of the past 20 years. Journal of Nervous Mental Disorders 188:187-201, 2000
8. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry 154(suppl 4):1-63, 1997
9. Frances A, Docherty JP, Kahn D: The expert consensus guideline series: treatment of schizophrenia. Journal of Clinical Psychiatry 57(suppl 12B):1-58, 1996
10. Lehman AF, Kreyenbuhl, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30:193-216, 2003
11. Rush AJ, Rago WV, Crismon ML, et al: Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Journal of Clinical Psychiatry 60:284-291, 1999
12. Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initials results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophrenia Bulletin 24:11-20, 1998
13. Walkup JT, McAlpine D, Olfson M, et al: Patients with schizophrenia at risk for excessive antipsychotic dosing. Journal of Clinical Psychiatry 61:344-348, 2000
14. Lehman AF, Steinwachs DM: Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry 31:141-154, 2003
15. Johnson PB, Ramirez PM, Opler LA, et al: Relationship between neuroleptic dose and positive and negative symptoms. Psychological Reports 74:481-482, 1994
16. Krakowski MI, Kunz M, Czobor P, et al: Long term high-dose neuroleptic treatment: who gets it and why? Hospital and Community Psychiatry 44:640-644, 1993
17. Segal SP, Cohen D, Marder SR: Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective. American Journal of Public Health 82:846-852, 1992
18. Baldessarini RJ, Katz B, Cotton P: Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry 141:748-752, 1984
19. Leslie DL, Rosenheck RA: Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Medical Care 39:907-909, 2001
20. Medicare: A Strategy for Quality Assurance: Vol 1. Edited by Lohr KN. Washington, DC, National Academy Press, 1990
21. Zarin DA, Pincus HA, Marcus SC: The Generalizability of Findings from Randomized Controlled Trials (RCTs) to Routine Clinical Settings. Boca Raton, Fla, National Clinical Drug Evaluations Unit, 1998
22. Olfson M, Klerman GL, Pincus HA: The roles of psychiatrists in organized outpatient mental health settings. American Journal of Psychiatry 150:625-631, 1993
23. Pincus HA, Zarin DA, Tanelian TL, et al: Psychiatric patients and treatments in 1997: findings from the American Psychiatric Practice Research Network. Archives of General Psychiatry 56:441-449, 1999
24. Zarin DA, Pincus HA, Peterson BD, et al: Characterizing psychiatry with findings from the 1996 National Survey of Psychiatric Practice. American Journal of Psychiatry 155:397-404, 1998
25. Shah BV, Barnwell BG, Bieler GS: SUDAAN User's Manual, Release 7.5 ed. Research Triangle Park, NC, Research Triangle Institute, 1997
26. Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated Treatment Recommendations 2003. Schizophrenia Bulletin 30:193-216, 2004
27. Citrome L, Levine J, Allingham B: Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacology Bulletin 32:321-326, 1996
28. Geddes J, Freemantle N, Harrison P, et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321:1371-1376, 2000
29. Young AS, Sullivan G, Burnam MA, et al: Measuring the quality of outpatient treatment for schizophrenia. Archives of General Psychiatry 55:611-617, 1998
30. Twanley EW, Jest DV, Lehman AF: Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. Journal of Nervous Mental Disorder 191:515-523, 2003
31. Bryson G, Bell MD: Initial and final work performance in schizophrenia: cognitive and symptoms predictors. Journal of Nervous Mental Disorder 191:87-92, 2003
32. Hoffman H, Kupper Z, Zbinden M, et al: Predicting vocational functioning and outcome in schizophrenia outpatients attending a vocational rehabilitation program. Social Psychiatry and Psychiatric Epidemiology 38:76-82, 2003
33. Bellack AS, Brown SA: Psychosocial treatments for schizophrenia. Current Psychiatry Reports 3:407-412, 2001
34. Voit S: Intervention options: participation in work activities for people with schizophrenia. Work 16:139-151, 2001